Skip to main content

Medical Oncology

Ausgabe 3/2018

Inhalt (23 Artikel)

Original Paper

Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia

Ana Paula Zambuzi Cardoso Marsola, Belinda Pinto Simões, Leonardo Carvalho Palma, Maria Gabriela Berzoti-Coelho, Sandra Mara Burin, Fabíola Attié de Castro

Original Paper

Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma

Giuseppina Improta, Angela Zupa, Maria Iole Natalicchio, Lorenza Sisinni, Anna Marinaccio, Giovanni Bozza, Giulia Vita, Michele Aieta, Matteo Landriscina

Original Paper

Efficacy of doxorubicin after progression on carboplatin and paclitaxel in advanced or recurrent endometrial cancer: a retrospective analysis of patients treated at the Brazilian National Cancer Institute (INCA)

Emeline Moreira, Eduardo Paulino, Álvaro Henrique Ingles Garces, Mariane S. Fontes Dias, Marcos Saramago, Flora de Moraes Lino da Silva, Luiz Claudio Santos Thuler, Andréia Cristina de Melo

Original Paper

Long-term survival with modern therapeutic agents against metastatic melanoma—vemurafenib and ipilimumab in a daily life setting

B. M. Lang, A. Peveling-Oberhag, D. Faidt, A. M. Hötker, V. Weyer-Elberich, S. Grabbe, C. Loquai

Original Paper

Genetic polymorphism of calcium-sensing receptor in women with breast cancer

Larysse Maira Campos-Verdes, João Paulo da Silva-Sampaio, Danylo Rafhael Costa-Silva, Victor Alves de Oliveira, Airton Mendes Conde Junior, Vladimir Costa Silva, Airlane Pereira Alencar, Viriato Campelo, Pedro Vitor Lopes-Costa, Luiz Henrique Gebrim, Benedito Borges da Silva

Original Paper

Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections

Daniel E. Spratt, Krithika Suresh, Takahiro Osawa, Matthew Schipper, William C. Jackson, Ahmed Abugharib, Amir Lebastchi, David Smith, Jeffrey S. Montgomery, Ganesh S. Palapattu, L. Priya Kunju, Angela Wu, Madelyn Lew, Scott A. Tomlins, Arul M. Chinnaiyan, Alon Z. Weizer, Khaled S. Hafez, Samuel D. Kaffenberger, Aaron Udager, Rohit Mehra

Original Paper

Prognostic value of epidermal growth factor receptor mutations and histologic subtypes with lung adenocarcinoma

Nozomu Motono, Aika Funasaki, Atsushi Sekimura, Katsuo Usuda, Hidetaka Uramoto

Original Paper

Factors involved in early lenvatinib dose reduction: a retrospective analysis

Koichi Suyama, Mai Tomiguchi, Takashi Takeshita, Aiko Sueta, Mutsuko Yamamoto-Ibusuki, Mototsugu Shimokawa, Yutaka Yamamoto, Hirotaka Iwase

Open Access Original Paper

Expression of gremlin1 in gastric cancer and its clinical significance

Yoichi Yamasaki, Sumiya Ishigami, Takaaki Arigami, Yoshiaki Kita, Yasuto Uchikado, Hiroshi Kurahara, Yuko Kijima, Kosei Maemura, Shoji Natsugoe

Original Paper

Combined pulmonary fibrosis and emphysema predicts recurrence following surgery in patients with stage I non-small cell lung cancer

Ryo Maeda, Aika Funasaki, Nozomu Motono, Atsushi Sekimura, Katsuo Usuda, Hidetaka Uramoto

Open Access Original Paper

Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer

Hannah Fuchs, Johannes Pammer, Christoph Minichsdorfer, Doris Posch, Gabriela Kornek, Marie-Bernadette Aretin, Thorsten Fuereder

Open Access Original Paper

A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations

Hisashi Tanaka, Kageaki Taima, Yoshihito Tanaka, Masamichi Itoga, Yoshiko Ishioka, Hideyuki Nakagawa, Keisuke Baba, Yukihiro Hasegawa, Shingo Takanashi, Sadatomo Tasaka

Original Paper

Can anticancer chemotherapy promote the progression of brain metastases?

Aymeric Amelot, Louis-Marie Terrier, Bertrand Mathon, Ann-Rose Cook, Jean-Jacques Mazeron, Charles-Ambroise Valery, Philippe Cornu, Marc Leveque, Alexandre Carpentier

Original Paper

Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase

Michihide Tokuhira, Yuta Kimura, Keiji Sugimoto, Tomonori Nakazato, Maho Ishikawa, Isao Fujioka, Tomoiku Takaku, Noriyoshi Iriyama, Eriko Sato, Hiroyuki Fujita, Yoshihiro Hatta, Norio Komatsu, Norio Asou, Masahiro Kizaki, Tatsuya Kawaguchi

Original Paper

Hypofractionated postmastectomy radiotherapy with helical tomotherapy in patients with immediate breast reconstruction: dosimetric results and acute/intermediate toxicity evaluation

Roberto Orecchia, Damaris Patricia Rojas, Federica Cattani, Rosalinda Ricotti, Luigi Santoro, Anna Morra, Raffaella Cambria, Rosa Luraschi, Samantha Dicuonzo, Sara Ronchi, Alessia Surgo, Veronica Dell’ Acqua, Paolo Veronesi, Francesca De Lorenzi, Cristiana Fodor, Maria Cristina Leonardi, Barbara Alicja Jereczek-Fossa

Original Paper

Knockdown of STEAP1 inhibits cell growth and induces apoptosis in LNCaP prostate cancer cells counteracting the effect of androgens

Inês Margarida Gomes, Sandra Moreira Rocha, Carlos Gaspar, Maria Inês Alvelos, Cecília Reis Santos, Sílvia Socorro, Cláudio Jorge Maia

Review Article

Cell biology of glioblastoma multiforme: from basic science to diagnosis and treatment

George S. Stoyanov, Deyan Dzhenkov, Peter Ghenev, Bogomil Iliev, Yavor Enchev, Anton B. Tonchev

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.